# Clinical, Immunological, Radiographic, and Pathologic Improvements in a Patient with Long-Standing Crohn’s Disease After Receiving Stem Cell Educator Therapy

**Authors:** Richard Fox, Boris Veysman, Kristine Antolijao, Noelle Mendoza, Ruby Anne Lorenzo, Honglan Wang, Zhi Hua Huang, Yelu Zhao, Yewen Zhao, Terri Tibbot, Darinka Povrzenic, Mary Lauren Bayawa, Sophia Kung, Bassam Saffouri, Yong Zhao

PMC · DOI: 10.3390/ijms26157292 · International Journal of Molecular Sciences · 2025-07-28

## TL;DR

A 78-year-old Crohn’s disease patient showed significant improvements in symptoms and inflammation after a single Stem Cell Educator therapy treatment.

## Contribution

Demonstrates the potential of Stem Cell Educator therapy to improve Crohn’s disease through clinical, immunological, and radiographic outcomes.

## Key findings

- Clinical symptoms like abdominal pain and rectal bleeding resolved after treatment.
- Inflammatory markers IL-1β+ and CXCL16+ cells decreased significantly.
- Pathological and radiographic evidence showed no inflammation or stenosis post-treatment.

## Abstract

Crohn’s disease is a chronic inflammation affecting the gastrointestinal tract. To date, patients are commonly treated with corticosteroids or more aggressive biologics for high-risk subjects. Stem Cell Educator therapy has been successfully utilized to treat patients with type 1 diabetes and other autoimmune conditions. A 78-year-old patient with long-standing Crohn’s disease received one treatment with the Stem Cell Educator therapy, followed by clinical, radiographic, pathological examinations and immune marker testing by flow cytometry. After the treatment with Stem Cell Educator therapy, the patient’s clinical symptoms were quickly improved with normal bowel movements, without abdominal pain or rectal bleeding. Flow cytometry analysis revealed a marked decline in inflammatory markers, such as the percentage of monocyte/macrophage-associated cytokine interleukin-1 beta (IL-1β)+ cells, which reduced from 94.98% at the baseline to 18.21%, and down-regulation of the percentage of chemokine CXCL16+ cells from 91.92% at baseline to 42.58% at 2-month follow-up. Pathologic examination of the biopsy specimens from colonoscopy five weeks and six months post-treatment showed ileal mucosa with no specific abnormality and no significant inflammation or villous atrophy; no granulomas were identified. A follow-up CT scan four and one-half months post-treatment showed no evidence of the previously seen stenosis of the ilio-colonic anastomosis with proximal dilatation. Stem Cell Educator therapy markedly reduced inflammation in the subject with Crohn’s disease, leading to durable clinical, immunological, radiographic, and pathological improvements.

## Linked entities

- **Proteins:** IL1B (interleukin 1 beta), CXCL16 (C-X-C motif chemokine ligand 16)
- **Diseases:** Crohn’s disease (MONDO:0005011)

## Full-text entities

- **Genes:** IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CXCL16 (C-X-C motif chemokine ligand 16) [NCBI Gene 58191] {aka CXCLG16, SR-PSOX, SRPSOX}
- **Diseases:** granulomas (MESH:D006099), villous atrophy (MESH:C564019), Crohn's Disease (MESH:D003424), abdominal pain (MESH:D015746), inflammation (MESH:D007249), stenosis (MESH:D003251), rectal bleeding (MESH:D012002), type 1 diabetes (MESH:D003922), autoimmune conditions (MESH:D001327)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12346882/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12346882/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12346882/full.md

---
Source: https://tomesphere.com/paper/PMC12346882